Cancer Type: Brain tumor, adult: Astrocytoma/Astrocytic tumors
Stage/Subtype of Cancer: anaplastic astrocytoma, adult
Country: U.S.A.
Trial Type: Treatment
Trial Status: Active
1.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: SJCRH-SJHG04, GENENTECH-OSI3160s, NCT00124657
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Other
Protocol IDs: CNS 0201, NCT00179907
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0063, NCI-P6680, NCT00293566
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 501007705, NCT00301418
|
|
5.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-0503, NCT00404248
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 120
Sponsor: Other
Protocol IDs: R01 CA 89395-01, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: 2006P-000464, NCT00456612
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0604104, OSI3781s, NCT00509431
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NU07C1, NU 07C1, NCT00516282
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: REO 007, NCT00528684
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N057K, N057K, NCT00553150
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0709, NCT00555399
|
|
13.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: ABTC-0703, NABTT-0703, NABTT-0703, NCT00589576
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 05-115, RO1 NS055140, NCT00766753
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-342, CLBH589BUS42T, NCT00859222
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-9, NCT00003457
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-15, NCT00003470
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-21, NCT00003475
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BC-BT-8, NCT00003537
|
|
20.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: OHSU-7328, OHSU-922, OHSU-ONC-02059-L, NCT00075387, CASE-CCF-6385
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-05-C-0137, NCT00112762
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CASE-CCF-7348, CCF-7348, NCT00243022, CASE1304200
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 05-079, NCT00200161
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NU-05C2, NCT00276783
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0064, NCI-P6762, NCT00290797
|
